CCCC Stock Summary and Trading Ideas (C4 Therapeutics | NASDAQ:CCCC)

C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

C4 Therapeutics trades on the NASDAQ stock market under the symbol CCCC.

As of January 6, 2025, CCCC stock price climbed to $4.09 with 1,202,647 million shares trading.

CCCC has a beta of 2.03, meaning it tends to be more sensitive to market movements. CCCC has a correlation of 0.09 to the broad based SPY ETF.

CCCC has a market cap of $288.71 million. This is considered a Small Cap stock.

Last quarter C4 Therapeutics reported $15 million in Revenue and -$.35 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.03.

In the last 3 years, CCCC traded as high as $31.33 and as low as $1.06.

The top ETF exchange traded funds that CCCC belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

CCCC has underperformed the market in the last year with a return of -36.1%, while the SPY ETF gained +28.7%. In the last 3 month period, CCCC fell short of the market, returning -24.0%, while SPY returned +4.2%. However, in the most recent 2 weeks CCCC has outperformed the stock market by returning +0.7%, while SPY returned +0.1%.

CCCC support price is $3.66 and resistance is $4.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CCCC shares will trade within this expected range on the day.